Beate S. Schultheis

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Dirk Strumberg · 4 shared papers, 2012–2020 · strength 0.21
   • Paper Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combin… DOI 10.3390/cancers12113130↗
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
   • Paper Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). DOI 10.1007/s10637-011-9665-x↗
2. Thomas Theodor Werner Seufferlein · 1 shared paper, 2020 · strength 0.10
   • Paper Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combin… DOI 10.3390/cancers12113130↗
3. Uwe Pelzer · 1 shared paper, 2020 · strength 0.10
   • Paper Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combin… DOI 10.3390/cancers12113130↗
4. Max Ernst Scheulen · 2 shared papers, 2012 · strength 0.06
   • Paper Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). DOI 10.1007/s10637-011-9665-x↗
   • Paper Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patient… DOI 10.1007/s10637-010-9619-8↗
5. Markus Dommach · 1 shared paper, 2017 · strength 0.05
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
6. Wolfgang Ekkehard Schmidt · 1 shared paper, 2017 · strength 0.05
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
7. Ralf‐Dieter Hofheinz · 1 shared paper, 2017 · strength 0.05
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
8. Sara De Dosso · 1 shared paper, 2017 · strength 0.05
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
9. Jens Thomas Siveke · 1 shared paper, 2017 · strength 0.05
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
10. Şuayib Yalçın · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
11. Lothar Bergmann · 1 shared paper, 2012 · strength 0.03
    • Paper Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). DOI 10.1007/s10637-011-9665-x↗
12. Klaus B. Mross · 1 shared paper, 2012 · strength 0.03
    • Paper Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patient… DOI 10.1007/s10637-010-9619-8↗
13. Florian Lordick · 1 shared paper, 2012 · strength 0.03
    • Paper Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patient… DOI 10.1007/s10637-010-9619-8↗
14. Norbert Walter Marschner · 1 shared paper, 2012 · strength 0.03
    • Paper Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patient… DOI 10.1007/s10637-010-9619-8↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.